
Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025
Description
Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on non-small cell lung cancer (nsclc) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Where is the largest and fastest growing market for non-small cell lung cancer (nsclc) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-small cell lung cancer (nsclc) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Markets Covered:1) By Type: Squamous Cell Carcinoma; Large Cell Carcinoma; Adenocarcinoma; Other Types
2) By Therapy: Radiotherapy; Laserthearpy; Photodynamic Therapy (PDT); Other Therapies
3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Other Distribution Channels
Subsegments:
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma; Non-Keratinizing Squamous Cell Carcinoma
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma; Large Cell Neuroendocrine Carcinoma
3) By Adenocarcinoma: Invasive Adenocarcinoma; Bronchioloalveolar Carcinoma
4) By Other Types: Mixed Cell Type Carcinoma; Sarcomatoid Carcinoma
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; GlaxoSmithKline Plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Viatris Inc; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc.; UCB S.A.; Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Aurobindo Pharma Limited; Cipla Limited; Ferring B.V.; Hikma Pharmaceuticals plc; Amneal Pharmaceuticals LLC; Zydus Lifesciences Ltd.; Lupin Limited; Torrent Pharmaceuticals Ltd.; Almirall S.A.; Clovis Oncology; Revolution Medicines
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.
This report focuses on non-small cell lung cancer (nsclc) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for non-small cell lung cancer (nsclc) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-small cell lung cancer (nsclc) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Markets Covered:1) By Type: Squamous Cell Carcinoma; Large Cell Carcinoma; Adenocarcinoma; Other Types
2) By Therapy: Radiotherapy; Laserthearpy; Photodynamic Therapy (PDT); Other Therapies
3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Other Distribution Channels
Subsegments:
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma; Non-Keratinizing Squamous Cell Carcinoma
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma; Large Cell Neuroendocrine Carcinoma
3) By Adenocarcinoma: Invasive Adenocarcinoma; Bronchioloalveolar Carcinoma
4) By Other Types: Mixed Cell Type Carcinoma; Sarcomatoid Carcinoma
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; GlaxoSmithKline Plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Viatris Inc; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc.; UCB S.A.; Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Aurobindo Pharma Limited; Cipla Limited; Ferring B.V.; Hikma Pharmaceuticals plc; Amneal Pharmaceuticals LLC; Zydus Lifesciences Ltd.; Lupin Limited; Torrent Pharmaceuticals Ltd.; Almirall S.A.; Clovis Oncology; Revolution Medicines
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Table of Contents
250 Pages
- 1. Executive Summary
- 2. Neuropathic Pain Market Characteristics
- 3. Neuropathic Pain Market Trends And Strategies
- 4. Neuropathic Pain Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
- 5. Global Neuropathic Pain Growth Analysis And Strategic Analysis Framework
- 5.1. Global Neuropathic Pain PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Neuropathic Pain Market Growth Rate Analysis
- 5.4. Global Neuropathic Pain Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Neuropathic Pain Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Neuropathic Pain Total Addressable Market (TAM)
- 6. Neuropathic Pain Market Segmentation
- 6.1. Global Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Medications
- Multimodal Therapy
- 6.2. Global Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Imaging
- Blood Tests And Physical Examination
- 6.3. Global Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Diabetic Neuropathy
- Spinal Stenosis
- Chemotherapy-Induced Peripheral Neuropathy
- Other Indications
- 6.4. Global Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Home Healthcare
- Ambulatory Surgical Centers
- Other End Users
- 6.5. Global Neuropathic Pain Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anticonvulsants
- Antidepressants
- Opioids
- Topical Treatments
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- 6.6. Global Neuropathic Pain Market, Sub-Segmentation Of Multimodal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Combination Of Medications
- Physical Therapy
- Psychological Therapy
- Lifestyle Modifications
- Complementary Therapies
- 7. Neuropathic Pain Market Regional And Country Analysis
- 7.1. Global Neuropathic Pain Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Neuropathic Pain Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8. Asia-Pacific Neuropathic Pain Market
- 8.1. Asia-Pacific Neuropathic Pain Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 9. China Neuropathic Pain Market
- 9.1. China Neuropathic Pain Market Overview
- 9.2. China Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 10. India Neuropathic Pain Market
- 10.1. India Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11. Japan Neuropathic Pain Market
- 11.1. Japan Neuropathic Pain Market Overview
- 11.2. Japan Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12. Australia Neuropathic Pain Market
- 12.1. Australia Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13. Indonesia Neuropathic Pain Market
- 13.1. Indonesia Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14. South Korea Neuropathic Pain Market
- 14.1. South Korea Neuropathic Pain Market Overview
- 14.2. South Korea Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15. Western Europe Neuropathic Pain Market
- 15.1. Western Europe Neuropathic Pain Market Overview
- 15.2. Western Europe Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16. UK Neuropathic Pain Market
- 16.1. UK Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17. Germany Neuropathic Pain Market
- 17.1. Germany Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18. France Neuropathic Pain Market
- 18.1. France Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19. Italy Neuropathic Pain Market
- 19.1. Italy Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20. Spain Neuropathic Pain Market
- 20.1. Spain Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21. Eastern Europe Neuropathic Pain Market
- 21.1. Eastern Europe Neuropathic Pain Market Overview
- 21.2. Eastern Europe Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22. Russia Neuropathic Pain Market
- 22.1. Russia Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23. North America Neuropathic Pain Market
- 23.1. North America Neuropathic Pain Market Overview
- 23.2. North America Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24. USA Neuropathic Pain Market
- 24.1. USA Neuropathic Pain Market Overview
- 24.2. USA Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25. Canada Neuropathic Pain Market
- 25.1. Canada Neuropathic Pain Market Overview
- 25.2. Canada Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26. South America Neuropathic Pain Market
- 26.1. South America Neuropathic Pain Market Overview
- 26.2. South America Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27. Brazil Neuropathic Pain Market
- 27.1. Brazil Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28. Middle East Neuropathic Pain Market
- 28.1. Middle East Neuropathic Pain Market Overview
- 28.2. Middle East Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29. Africa Neuropathic Pain Market
- 29.1. Africa Neuropathic Pain Market Overview
- 29.2. Africa Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 30. Neuropathic Pain Market Competitive Landscape And Company Profiles
- 30.1. Neuropathic Pain Market Competitive Landscape
- 30.2. Neuropathic Pain Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
- 31. Neuropathic Pain Market Other Major And Innovative Companies
- 31.1. GlaxoSmithKline Plc
- 31.2. Medtronic Inc.
- 31.3. Eli Lilly and Company
- 31.4. Stryker Corporation
- 31.5. Baxter International Inc.
- 31.6. Teva Pharmaceutical Industries Ltd
- 31.7. Boston Scientific Corporation
- 31.8. Biogen Inc.
- 31.9. Zimmer Biomet Holdings Inc.
- 31.10. Sun Pharmaceutical Industries Ltd.
- 31.11. Mallinckrodt Pharmaceuticals
- 31.12. Grünenthal GmbH
- 31.13. Lupin Ltd.
- 31.14. NuVasive Inc.
- 31.15. Integer Holdings Corporation
- 32. Global Neuropathic Pain Market Competitive Benchmarking And Dashboard
- 33. Key Mergers And Acquisitions In The Neuropathic Pain Market
- 34. Recent Developments In The Neuropathic Pain Market
- 35. Neuropathic Pain Market High Potential Countries, Segments and Strategies
- 35.1 Neuropathic Pain Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Neuropathic Pain Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Neuropathic Pain Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
- 36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.